These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 928488)

  • 1. Stereoselective effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) on schedule-controlled behavior.
    Harris RA; Snell D; Loh HH
    Pharmacol Biochem Behav; 1977 Oct; 7(4):307-10. PubMed ID: 928488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of d-lysergic acid diethylamide (LSD), 2,5-dimethoxy-4-methylamphetamine (DOM) and d-amphetamine on operant responding in control and 6-hydroxydopamine-treated rats.
    Commissaris R; Lyness WH; Cordon JJ; Moore KE; Rech RH
    Pharmacol Biochem Behav; 1980 Nov; 13(5):621-6. PubMed ID: 7443731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DOM-stimulus generalization to LSD and other hallucinogenic indolealkylamines.
    Glennon RA; Young R; Jacyno JM; Slusher M; Rosecrans JA
    Eur J Pharmacol; 1983 Jan; 86(3-4):453-9. PubMed ID: 6572591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis.
    Sanders-Bush E; Burris KD; Knoth K
    J Pharmacol Exp Ther; 1988 Sep; 246(3):924-8. PubMed ID: 2843634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The time-dependent stimulus effects of R(-)-2,5-dimethoxy-4-methamphetamine (DOM): implications for drug-induced stimulus control as a method for the study of hallucinogenic agents.
    Fiorella D; Palumbo PA; Rabin RA; Winter JC
    Psychopharmacology (Berl); 1995 May; 119(2):239-45. PubMed ID: 7659772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of the behavioral effects of 2,5-dimethoxy-4-methyl-amphetamine (DOM) by pretreatment with p-chlorophenylalanine.
    Commissaris RL; Lyness WH; Moore KE; Rech RH
    Pharmacol Biochem Behav; 1980 Oct; 13(4):605-8. PubMed ID: 6449015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of 2,5-dimethoxy-4-methylamphetamine (DOM) on operant behavior: interactions with other neuroactive agents.
    Commissaris RL; Semeyn DR; Moore KE; Rech RH
    Commun Psychopharmacol; 1980; 4(5):393-404. PubMed ID: 6120791
    [No Abstract]   [Full Text] [Related]  

  • 8. Naloxone alters the effects of LSD, DOM and quipazine on operant behavior of rats.
    Mokler DJ; Commissaris RL; Henck JW; Rech RH
    Pharmacol Biochem Behav; 1984 Sep; 21(3):333-7. PubMed ID: 6593750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of 2,3-dihydrobenzofuran analogues of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane: drug discrimination studies in rats.
    Nichols DE; Hoffman AJ; Oberlender RA; Riggs RM
    J Med Chem; 1986 Feb; 29(2):302-4. PubMed ID: 3950910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral effects of intracerebroventricular administration of LSD, DOM, mescaline or lisuride.
    Mokler DJ; Rech RH
    Pharmacol Biochem Behav; 1984 Aug; 21(2):281-7. PubMed ID: 6483939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of intracranial administration of hallucinogens on operant behavior in the rat. II. 2,5-Dimethoxy-4-methylamphetamine (DOM).
    Mokler DJ; Stoudt KW; Sherman LC; Rech RH
    Pharmacol Biochem Behav; 1987 Nov; 28(3):327-34. PubMed ID: 3685066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulus effects of ibogaine in rats trained with yohimbine, DOM, or LSD.
    Palumbo PA; Winter JC
    Pharmacol Biochem Behav; 1992 Dec; 43(4):1221-6. PubMed ID: 1475306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDA and DOM: substituted amphetamines that do not produce amphetamine-like discriminative stimuli in the rat.
    Shannon HE
    Psychopharmacology (Berl); 1980; 67(3):311-2. PubMed ID: 6770411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral and neuropharmacological analysis of amphetamine and 2,5-dimethoxy-4-methylamphetamine in rats.
    Tilson HA; Baker TG; Chamberlain JH
    Psychopharmacologia; 1975 Nov; 44(3):229-39. PubMed ID: 1208759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioral characterization of 2-O-desmethyl and 5-O-desmethyl metabolites of the phenylethylamine hallucinogen DOM.
    Eckler JR; Chang-Fong J; Rabin RA; Smith C; Teitler M; Glennon RA; Winter JC
    Pharmacol Biochem Behav; 2003 Jul; 75(4):845-52. PubMed ID: 12957227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1-(2,3-Methylenedioxyphenyl)-2-aminopropane (2,3-MDA): a preliminary investigation.
    Glennon RA; Young R; Soine W
    Gen Pharmacol; 1984; 15(4):361-2. PubMed ID: 6149169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral comparisons of R-2-amino-1-(2,5-dimethoxy-4-methylphenyl) butane (BL-3912A) with R-DOM and S-amphetamine.
    Tilson HA; Chamberlain JH; Gylys JA
    Psychopharmacology (Berl); 1977 Jan; 51(2):169-73. PubMed ID: 402669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of d-lysergic acid diethylamide (LSD), 2,5-dimethoxy-4-methylamphetamine (DOM), pentobarbital and methaqualone on punished responding in control and 5,7-dihydroxytryptamine-treated rats.
    Commissaris RL; Lyness WH; Rech RH
    Pharmacol Biochem Behav; 1981 May; 14(5):617-23. PubMed ID: 7243840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of d-amphetamine, monomethoxyamphetamines and hallucinogens on schedule-controlled behavior.
    Harris RA; Snell D; Loh HH
    J Pharmacol Exp Ther; 1978 Jan; 204(1):103-17. PubMed ID: 619124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the discriminative stimulus properties of R-2,5-dimethoxy-4-methylamphetamine (R-DOM) and S-amphetamine in the rat.
    Tilson HA; Baker TG; Gylys JA
    Psychopharmacologia; 1975 Nov; 44(3):225-8. PubMed ID: 1208758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.